- Conditions
- Achondroplasia
- Interventions
- Not listed
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Oakland, California • Wilmington, Delaware + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 5,340
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sexual Dysfunction, Psychological
- Interventions
- Non-prescription Zestra(TM): patented formulation
- Drug
- Lead sponsor
- QualiLife Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 65 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 13
- States / cities
- Tarzana, California • Aurora, Colorado • Aventura, Florida + 10 more
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- becatecarin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 198
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more
- Conditions
- Heart Failure, Congestive, Ventricular Dysfunction, Cardiomyopathies
- Interventions
- Thoratec HeartMate II Left Ventricular Assist System (LVAS)
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- Not listed
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 30 more
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma, Ureter Carcinoma, Urinary Bladder Carcinoma, Urethra Carcinoma, Muscle Invasive Bladder Cancer
- Interventions
- Rucaparib
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 41
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 35 more
- Conditions
- Type 2 Diabetes Mellitus, Heart Failure
- Interventions
- Saxagliptin, Sitagliptin, Placebo to match saxagliptin, Placebo to match sitagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 11
- States / cities
- Torrance, California • Upland, California • Miami, Florida + 7 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Sonrotoclax, Zanubrutinib, Acalabrutinib, Venetoclax
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 22
- States / cities
- Duarte, California • Orange, California • Palo Alto, California + 19 more
- Conditions
- Motor Neuron Disease
- Interventions
- FLX-787-ODT (orally disintegrating tablet), Placebo ODT
- Drug
- Lead sponsor
- Flex Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 35
- States / cities
- Scottsdale, Arizona • Sacramento, California • San Francisco, California + 29 more
- Conditions
- Ganglioneuroblastoma, Recurrent Neuroblastoma
- Interventions
- Dinutuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Sargramostim, Temozolomide, Temsirolimus
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 136
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Downey, California + 106 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, rosiglitazone, metformin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 71
- States / cities
- Goodyear, Arizona • Colton, California • Concord, California + 59 more
- Conditions
- NYHA Class III Heart Failure, NYHA Class IV Heart Failure
- Interventions
- Optimizer System, No intervention: Optimal medical therapy
- Device · Other
- Lead sponsor
- Impulse Dynamics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 32
- States / cities
- Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 26 more
- Conditions
- Adenocarcinoma
- Interventions
- Epirubicin with Cyclophosphamide, followed by a Taxane, Epirubicin with a Taxane
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 54
- States / cities
- Mobile, Alabama • Tucson, Arizona • Bakersfield, California + 49 more
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 0 Years to 21 Years
- Enrollment
- 1,260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Denver, Colorado • Boston, Massachusetts + 7 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Calderasib, Pembrolizumab, carboplatin, pemetrexed, cetuximab, oxaliplatin, leucovorin, 5-fluorouracil
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Grand Rapids, Michigan • Hackensack, New Jersey + 3 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 82
- States / cities
- Chandler, Arizona • Little Rock, Arkansas • Bell Gardens, California + 71 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Talquetamab, Teclistamab, Pomalidomide
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 10
- States / cities
- Duarte, California • Irvine, California • San Francisco, California + 6 more
- Conditions
- COVID-19
- Interventions
- Shionogi Protease Inhibitor (S-217622), placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fresno, California + 75 more
- Conditions
- Emphysema
- Interventions
- Spiration Valve System, Medical Management
- Device · Other
- Lead sponsor
- Olympus Corporation of the Americas
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 32
- States / cities
- Fort Smith, Arkansas • Riverside, California • San Diego, California + 28 more
- Conditions
- Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, yttrium Y 90 ibritumomab tiuxetan
- Biological · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 58 more
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Interventions
- Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,059 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 221
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease
- Interventions
- Nitroglycerin, Topical AmphiMatrix
- Drug
- Lead sponsor
- MediQuest Therapeutics
- Industry
- Eligibility
- 15 Years to 70 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 17
- States / cities
- Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
- Conditions
- End of Life, Communication, Cancer Metastatic
- Interventions
- Novel Communication Intervention, Enhanced Usual Care Parent Education
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Wilmington, Delaware • Atlanta, Georgia + 4 more
- Conditions
- Kidney Cancer
- Interventions
- dactinomycin, filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 0 Years to 15 Years
- Enrollment
- 3,031 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2003
- U.S. locations
- 206
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Multiple Myeloma
- Interventions
- STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)
- Drug
- Lead sponsor
- Poniard Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Orange, California • Denver, Colorado + 17 more